TITLE

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update

AUTHOR(S)
Scott, S A; Sangkuhl, K; Stein, C M; Hulot, J‐S; Mega, J L; Roden, D M; Klein, T E; Sabatine, M S; Johnson, J A; Shuldiner, A R
PUB. DATE
September 2013
SOURCE
Clinical Pharmacology & Therapeutics;Sep2013, Vol. 94 Issue 3, p317
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Cytochrome P450 (CYP)2C19 catalyzes the bioactivation of the antiplatelet prodrug clopidogrel, and CYP2C19 loss-of-function alleles impair formation of active metabolites, resulting in reduced platelet inhibition. In addition, CYP2C19 loss-of-function alleles confer increased risks for serious adverse cardiovascular (CV) events among clopidogrel-treated patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI). Guideline updates include emphasis on appropriate indication for CYP2C19 genotype-directed antiplatelet therapy, refined recommendations for specific CYP2C19 alleles, and additional evidence from an expanded literature review (updates at http://www.pharmgkb.org).
ACCESSION #
89806864

 

Related Articles

  • Progress of Antiplatelet Pharmacogenomics. Oestreich, Julie H. // Current Drug Targets;Nov2011, Vol. 12 Issue 12, p1848 

    Numerous genetic variants have been studied in the context of antiplatelet responsiveness, particularly for aspirin and clopidogrel. The majority of these variants have failed to demonstrate any measurable level of clinical validity with the exception of the CYP2C19*2 allele. Several studies...

  • Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? Perry, Christina G; Shuldiner, Alan R // Journal of Human Genetics;Jun2013, Vol. 58 Issue 6, p339 

    Pharmacogenomics, the study of the genomics of drug response and adverse effects, holds great promise for more effective individualized (personalized) medicine. Recent evidence supports a role of loss-of-function (LOF) variants in the cytochrome P450 enzyme CYP2C19 as a determinant of...

  • Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Scott, S A; Martis, S; Peter, I; Kasai, Y; Kornreich, R; Desnick, R J // Pharmacogenomics Journal;Aug2012, Vol. 12 Issue 4, p297 

    CYP2C19 is a principal enzyme involved in the bioactivation of the antiplatelet prodrug clopidogrel and common CYP2C19 loss-of-function alleles are associated with adverse cardiovascular events. To assess the impact of the CYP2C19*17 increased activity allele in the Ashkenazi Jewish (AJ) and...

  • SHORT CUTS. Fister, Kristina // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/5/2009, Vol. 339 Issue 7720, p536 

    This section discusses various health-related studies published in different journals. A study published in the "New England Journal of Medicine" estimated the cumulative doses of radiation received by patients in the U.S. during imaging procedures. Another study published in the same journal...

  • Effect of CYP2C19 variants on clopidogrel.  // Clinical Cardiology Alert;Nov2009 Clinical Briefs, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

  • Effect of CYP2C19 variants on clopidogrel. Kuritzky, Louis // Primary Care Reports;Nov2009 Primary Care, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

  • Effect of CYP2C19 variants on clopidogrel.  // Clinical Oncology Alert;Nov2009 Supplement, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

  • Effect of CYP2C19 variants on clopidogrel. Kuritzky, Louis // Neurology Alert;Nov2009 Primary Care, p21 

    The article discusses research on the impact of cytochrome P450 2C19 (CYP2C19) variants on clopidopgrel (CPG). It references a study by A. R. Shuldiner et al published in a 2009 issue of the "Journal of the American Medical Association " (JAMA). It found that genetic variations in the cytochrome...

  • Antiplatelet Effect of Clopidogrel Can Be Reduced by Calcium-Channel Blockers. Kwon-Duk Seo; Young Dae Kim; Young-Won Yoon; Jong-Youn Kim; Kyung-Yul Lee // Yonsei Medical Journal;May2014, Vol. 55 Issue 3, p683 

    Purpose: Clopidogrel is metabolized by the hepatic cytochrome P450 (CYP) system into its active thiol metabolite. CYP3A4 is involved in the metabolism of both clopidogrel and dihydropyridine calcium channel blockers (CCBs). A few reports have suggested an inhibitory interaction between CCBs and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics